Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Guillaume Cartron, Paolo Corradini, Nancy L. Bartlett, Gloria Iacoboni, Cyrus Khan, Mark S. Hertzberg, Lorenzo Falchi, Joshua Brody, Marek Trněný, Estefania Mulvihill, Aurelien Berthier, Alessia Bottos, James Relf, Fabiola Bene Tchaleu, Linda Lundberg, Martin Hutchings
Institutions: The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, IRCCS Humanitas Research Hospital, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Montpellier, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Washington University in St. Louis, Vall d'Hebron Hospital Universitari, Allegheny Health Network, UNSW Sydney, Prince of Wales Hospital, Memorial Sloan Kettering Cancer Center, Tisch Cancer Institute, Charles University, Roche (Switzerland), Roche (United Kingdom), Annexon Biosciences (United States), Rigshospitalet
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405043379